Q32 Bio Inc.

QTTB

Q32 Bio Inc.

QTTB

Insider Sentiment (TTM):

Last Purchase:2026-05-28Last Sale:2026-02-25Shares Purchased (TTM):3,750,000Shares Sold (TTM):48,284

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:9,217,954Shares Outstanding:14,095,371Institutional Ownership Pct.:65.40%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	106	51	48	49	55	65	78	89	98	116	26	36
Short Term Investments	-	-	-	-	-	-	-	-	-	-	-	74
Available For Sale Securities Debt Securities Curr…	-	-	-	-	-	-	-	-	10	20	43	-
Prepaid Expense And Other Assets Current	3	6	7	2	3	3	4	5	4	3	3	3
Assets Current	110	57	55	51	58	69	82	94	112	138	29	107
Equity Method Investments	-	-	-	-	-	-	-	-	-	-	-	14
Assets Held For Sale Not Part Of Disposal Group	-	-	-	-	-	-	-	-	-	-	0	0
Equity Method Investment Aggregate Cost	-	-	0	0	0	3	3	3	3	5	0	-
Property Plant And Equipment Net	1	1	1	1	1	1	1	1	2	2	2	0
Operating Lease Right Of Use Asset	5	5	5	5	5	6	6	6	6	6	6	19
Restricted Cash And Cash Equivalents Noncurrent	1	1	1	1	1	1	1	1	1	1	6	-
Other Assets Noncurrent	-	-	0	0	1	0	0	0	1	1	5	-
Assets	116	64	62	58	66	79	92	105	124	152	47	140
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	2	1	1	1	1	3	3	1	2	5	3	8
Operating Lease Liability Current	-	-	-	-	-	-	-	-	-	-	1	2
Lines Of Credit Current	0	6	6	6	6	5	3	2	0	3	1	-
Contract With Customer Liability Current	-	-	-	-	-	-	-	-	-	-	0	0
Liabilities Current	5	11	11	11	12	15	16	14	17	33	14	25
Liabilities Noncurrent
Operating Lease Liability Noncurrent	5	5	5	5	5	5	6	6	6	6	6	27
Long Term Line Of Credit	0	2	3	5	7	8	10	11	13	9	5	-
Convertible Debt Noncurrent	-	-	-	-	-	-	0	0	0	0	39	-
Other Liabilities Noncurrent	-	-	0	55	55	55	55	55	55	55	55	-
Liabilities	10	17	20	76	78	83	87	86	91	104	119	52
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	-	-	-	0	0
Temporary Equity Carrying Amount Attributable To P…	-	-	-	-	-	-	0	0	0	0	111	-
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	327	259	247	244	243	242	240	239	237	235	4	614
Accumulated Other Comprehensive Income Loss Net Of…	-	-	-	0	0	0	0	-0	-0	-0	0	-0
Retained Earnings Accumulated Deficit	-222	-213	-205	-263	-255	-246	-235	-221	-203	-186	-187	-526
Stockholders Equity	106	46	42	-18	-12	-4	6	18	34	49	-183	-156
Liabilities And Stockholders Equity	116	64	62	58	66	79	92	105	124	152	47	140
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	-	-	-	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	-	-	-	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	-	-	-	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	-	-	-	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	400	400	400	400	400	400	400	400	400	400	400	200
Common Stock Shares Issued	24	15	13	12	12	12	12	12	12	12	0	58
Shares Outstanding	24	15	13	12	12	12	12	12	12	12	0	58

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	114.98%	156.23%	194.75%	-	-	-	-	-	-	-	-	-
2025	12.34%	-5.84%	43.51%	-12.31%	-3.08%	52.31%	50.23%	55.66%	75.57%	6.51%	-15.86%	84.47%
2024	-4.85%	-33.02%	35.19%	21.35%	28.38%	41.19%	-43.30%	-92.92%	-92.58%	-13.68%	-13.68%	-8.95%
2023	-	-	-	-1.69%	-5.93%	-11.86%	-45.39%	-39.22%	-31.37%	23.44%	56.23%	55.68%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	20.30	5.36	4.85	4.57	5.06	4.71	4.97	6.53	6.49	4.19	2.04	4.22
Quick Ratio	19.68	4.76	4.26	4.41	4.75	4.49	4.74	6.19	6.26	4.11	1.82	4.10
Working Capital	104.25M	46.53M	43.70M	39.70M	46.79M	54.05M	65.41M	79.52M	94.43M	105.09M	14.61M	81.34M
Leverage & Debt
Debt to Equity	0.09	0.37	0.47	-4.13	-6.40	-20.70	15.27	4.71	2.71	2.12	-0.65	-0.33
Debt Ratio	0.09	0.27	0.32	1.32	1.19	1.05	0.94	0.82	0.73	0.68	2.52	0.37
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.08	-0.06	-0.05	-0.04	0.03
Per Share Metrics
Diluted EPS TTM	1.66	2.36	2.42	-3.44	-4.29	-4.90	-4.94	-5.02	-4.77	-19.65	-153.96	-176.07
Free Cash Flow Per Share TTM	-1.28	-1.94	-2.73	-2.15	-3.42	-5.39	-7.27	-5.55	-2.64	-20.83	-53.53	-101.58
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-	-	-	777.58%	778.16%	681.65%	923.01%	-1,030.40%
Net Profit Margin TTM	-	-	-	-	-	-	-	609.03%	668.86%	561.17%	1,027.98%	-1,103.35%
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-100.00%	-100.00%	-100.00%	-100.00%	-280.09%	-273.88%	-252.72%	-262.97%	72.26%
Net Income Growth (1Y)	-164.60%	-155.60%	-162.47%	-30.54%	-8.31%	30.34%	-11.18%	-0.59%	-29.28%	-55.87%	973.79%	1,320.24%
EPS Growth (1Y)	-138.73%	-148.11%	-147.34%	-31.48%	-10.07%	-89.37%	-96.67%	-97.15%	-97.94%	-84.72%	176,474.44%	235,510.04%
Valuation Metrics
P/E TTM	7.67	2.72	1.37	-0.58	-0.35	-0.34	-0.67	-8.89	-3.76	-0.37	-0.07	-0.12
P/B TTM	2.45	1.95	0.97	-1.31	-1.49	-5.01	5.65	29.45	6.41	0.35	-0.02	-0.05
P/S TTM	-	-	-	-	-	-	-	-54.14	-25.18	-2.07	-0.73	1.32
Market Cap	259.16M	90.49M	40.84M	24.24M	18.17M	20.13M	32.06M	538.85M	214.76M	16.96M	3.82M	7.29M
Enterprise Value	152.24M	45.33M	-1.87M	-19.22M	-31.08M	-41.34M	-43.45M	450.66M	116.45M	-96.11M	12.03M	-34.61M
Calculated Values
Free Cash Flow TTM	-25.97M	-27.40M	-33.54M	-26.31M	-41.66M	-65.72M	-67.79M	-67.08M	-31.60M	-20.73M	-18.68M	-35.18M
Net Debt	-106.92M	-45.16M	-42.71M	-43.45M	-49.25M	-61.47M	-75.52M	-88.19M	-98.31M	-113.07M	8.21M	-41.90M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-28Purchase

Owner: Xu, Diyong

Title: -

Shares: 1,875,000

Price/Share: $8.00

Value: $15,000,000.00

Shares Owned: 3,502,987

Relationship: Director,TenPercentOwner

Ownership: Indirect

2026-05-28Purchase

Owner: Orbimed, Capital Gp Vii L…

Title: -

Shares: 1,875,000

Price/Share: $8.00

Value: $15,000,000.00

Shares Owned: 3,502,987

Relationship: Director,TenPercentOwner

Ownership: Indirect

2026-02-25Sale

Owner: Morrison, Jodie Pope

Title: CEO

Shares: 9,896

Price/Share: $4.51

Value: $44,630.96

Shares Owned: 89,104

Relationship: Director,Officer

Ownership: Direct

2026-02-25Sale

Owner: Kalowski, Lee

Title: CFO and President

Shares: 3,995

Price/Share: $4.51

Value: $18,017.45

Shares Owned: 35,943

Relationship: Officer

Ownership: Direct

2026-02-25Sale

Owner: Violette, Shelia M.

Title: Chief Scientific Officer

Shares: 2,815

Price/Share: $4.51

Value: $12,695.65

Shares Owned: 55,569

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-28	Xu, Diyong	Director,TenPercentOwner	-	Indirect	Purchase	1,875,000	8.00	$15,000,000.00	3,502,987	4
2026-05-28	Orbimed, Capital Gp Vii L…	Director,TenPercentOwner	-	Indirect	Purchase	1,875,000	8.00	$15,000,000.00	3,502,987	4
2026-02-25	Morrison, Jodie Pope	Director,Officer	CEO	Direct	Sale	9,896	4.51	$44,630.96	89,104	4
2026-02-25	Kalowski, Lee	Officer	CFO and President	Direct	Sale	3,995	4.51	$18,017.45	35,943	4
2026-02-25	Violette, Shelia M.	Officer	Chief Scientific Officer	Direct	Sale	2,815	4.51	$12,695.65	55,569	4
2025-12-02	Kalowski, Lee	Officer	CFO and President	Direct	Sale	9,072	3.46	$31,389.12	39,938	4
2025-12-02	Morrison, Jodie Pope	Director,Officer	CEO	Direct	Sale	22,506	3.46	$77,870.76	99,000	4
2025-08-26	Violette, Shelia M.	Officer	Chief Scientific Officer	Direct	Sale	2,990	1.80	$5,382.00	58,384	4
2025-08-26	Morrison, Jodie Pope	Director,Officer	CEO	Direct	Sale	10,494	1.80	$18,889.20	121,506	4
2025-08-26	Kalowski, Lee	Officer	CFO and President	Direct	Sale	4,240	1.80	$7,632.00	49,010	4
2024-03-25	Tzianabos, Arthur	Director	-	Direct	Sale	265	24.20	$6,413.00	7,983	4
2024-03-25	Michaud, Charles Jr	Officer	See Remarks	Direct	Sale	75	24.20	$1,815.00	927	4
2024-03-25	Alloway, Paul	Officer	See Remarks	Direct	Sale	268	24.21	$6,488.28	2,596	4
2024-01-09	Tzianabos, Arthur	Director	-	Direct	Sale	13,037	0.57	$7,431.09	128,778	4
2024-01-03	Alloway, Paul	Officer	See Remarks	Direct	Sale	7,280	0.57	$4,149.60	28,036	4
2024-01-03	Michaud, Charles Jr	Officer	See Remarks	Direct	Sale	1,708	0.57	$973.56	11,598	4
2023-09-06	Seymour, Albert	Director,Officer	See Remarks	Direct	Sale	1,448	1.15	$1,665.20	150,874	4
2023-08-03	Jordan, Julie	Officer	Chief Medical Officer	Direct	Sale	1,853	1.39	$2,575.67	3,882	4
2023-08-02	Jordan, Julie	Officer	Chief Medical Officer	Direct	Sale	99	1.31	$129.69	2,770	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

65.40%

Inst. Shares: 9,217,954

Shares Outstanding: 14,095,371

2025-12-31

64.80%

Inst. Shares: 7,970,817

Shares Outstanding: 12,300,568

2025-09-30

68.49%

Inst. Shares: 8,383,459

Shares Outstanding: 12,240,542

2025-06-30

73.31%

Inst. Shares: 8,942,008

Shares Outstanding: 12,197,615

2025-03-31

81.17%

Inst. Shares: 9,900,485

Shares Outstanding: 12,197,615

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	9,217,954	14,095,371	65.40%
2025-12-31	7,970,817	12,300,568	64.80%
2025-09-30	8,383,459	12,240,542	68.49%
2025-06-30	8,942,008	12,197,615	73.31%
2025-03-31	9,900,485	12,197,615	81.17%
2024-12-31	11,520,586	9,320,884	123.60%
2024-09-30	9,635,373	12,076,412	79.79%
2024-06-30	8,022,930	11,964,224	67.06%
2024-03-31	7,393,620	995,280	-
2023-12-31	17,760,502	349,060	-
2023-09-30	16,780,026	346,288	-
2023-06-30	16,645,647	347,936	-
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Q32 Bio Inc. (QTTB) — SEC Financial Statements & Analysis

Q32 Bio Inc. (QTTB) is a pharmaceutical preparations company, incorporated in DE. Q32 Bio Inc. trades on Nasdaq as: QTTB. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Q32 Bio Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.09x, a Price-to-Sales (P/S) ratio of -54.14x (TTM), a Price-to-Book (P/B) ratio of 2.45x (TTM), at a market cap of $259.16M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.09x
P/S TTM: -54.14x
P/B TTM: 2.45x
Market Cap: $259.16M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Q32 Bio Inc. in?

Q32 Bio Inc. (QTTB) operates in the Pharmaceutical Preparations industry.

What is QTTB's market cap?

Q32 Bio Inc. (QTTB) has a market capitalization of $259.16M as of 2026-06-30.

What is QTTB's P/E ratio?

Q32 Bio Inc. (QTTB)'s trailing twelve month P/E ratio is 7.67x as of 2026-06-30.

What exchange does QTTB trade on?

Q32 Bio Inc. (QTTB) trades on the Nasdaq.

Where is Q32 Bio Inc. incorporated?

Q32 Bio Inc. is incorporated in DE.

Q32 Bio Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

Q32 Bio Inc. (QTTB) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.
Main Street's price.

Q32 Bio Inc. (QTTB) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.